Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field. It will be an interesting year ahead. Here's a look at last year's results, and an analysis of where they point. Read the report >>
Two top research organizations have mounted a combined effort to discover new drugs for cancer, Alzheimer's disease and other illnesses.
In addition to engineering a potential sale of Optimer Pharmaceuticals, new Chairman and CEO Henry McKinnell shed more light on the alleged misdeeds involving stock grants at the highest levels of the company, Xconomy 's Bruce Bigelow reported.
For years now Big Pharma companies have been pouring billions into ambitious new research efforts in China, anxious to capitalize on one of the world's most tantalizing emerging markets. Now Pfizer officials are indicating that they plan to follow up with new collaborations in research and marketing with Chinese partners as they ally themselves with a new generation of Chinese companies.
Pfizer this morning confirmed that it is closing one of its R&D sites in San Diego, shuttering its CovX operation a little more than four years after the pharma giant bought the biotech operation and added it to a new biologics initiative based in California.
Computer-designed drugs have come of age. More than two decades after industry pioneer Joshua Boger set sail from Merck to start Vertex Pharmaceuticals ($VRTX) to advance structure-based drug design, the industry has seen multiple drugs discovered with the help of computers reach the finish line with FDA approvals.
Pfizer says the painful cutting at its R&D operations in Connecticut is finally over. And the budget ax evidently cut a little deeper than expected.
As the drug giant seeks to carve out more than $1 billion for its budget, Pfizer confirmed plans to exit a clinical research operation in Singapore.
With pharma interest in rare-disease drugs becoming quite common, Protalix BioTherapeutics, maker of a rare disease drug partnered with Pfizer ($PFE), said today that it has hired Citigroup to help review "a broad array of product partnering, technology sharing and other strategic alternatives" for the Israel-based biotech company.
Stock for Pfizer's animal health spinoff Zoetis soared 21% after raising more than $2.2 billion in its initial public offering.